cytogenetic abnormality造句

• The 11q13 and 6p21 cytogenetic abnormalities are associated with a better prognosis.
• In the hematological cancers such as multiple myeloma cytogenetic abnormalities are very common due to the inherent nature of DNA breaks needed for immunoglobulin gene rearrangement.
• It was approved by the FDA on December 27, 2005 for patients with low or intermediate-1 risk MDS with 5q-with or without additional cytogenetic abnormalities.
• EFS was differentially expressed in the GEP1 and GEP3 groups, which were associated with worse prognosis, with more significant cytogenetic abnormalities and genomic instabilities observed in this groups.
• The crucial goal of a targeted microarray in medical practice is to provide clinically useful results for diagnosis, genetic counseling, prognosis, and clinical management of unbalanced cytogenetic abnormalities.
• Breakage-fusion-bridge creates several identi
  鸻ble cytogenetic abnormalities, such as anaphase bridges and dicentric chromosomes, which can be seen in progress using methods that have been available for decades.
• This cytogenetic abnormality has been found in 90 % of M2 acute myeloblastic leukemia; while the other 10 % constitutes a mix of M1 and M4 acute myeloid leukemia ( GFHC, 1990 ).
• Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low-or Intermediate-1-risk deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
• Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low-or Intermediate-1-risk deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
• In December 2005, Celgene received approval from the FDA to market Revlimid for the treatment of patients with transfusion-dependent anemia due to Low-or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
• In December 2005, Celgene received approval from the FDA to market Revlimid for the treatment of patients with transfusion-dependent anemia due to Low-or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
• The 15q11.2 BP1 BP2 microdeletion ( Burnside-Butler syndrome ) was the most common cytogenetic abnormality found in a recent study of 10, 351 consecutive patients presenting for genetic laboratory testing using ultra-high resolution chromosomal microarray analysis optimized for neurodevelopmental disorders and having autism spectrum disorders ( ASD ).
• A completed Phase II, multi-centre, single-arm, open-label study evaluated the efficacy and safety of Revlimid monotherapy treatment for achieving haematopoietic improvement in red blood cell ( RBC ) transfusion dependent subjects with low-or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality.
• Lenalidomide was approved on June 17, 2013 by the European Medicines Agency for use in low-or intermediate-1-risk myelodysplastic syndromes ( MDS ) patients who have the deletion 5q cytogenetic abnormality and no other cytogenetic abnormalities, are dependent on red blood cell transfusions, and for whom other treatment options have been found to be insufficient or inadequate.
• Lenalidomide was approved on June 17, 2013 by the European Medicines Agency for use in low-or intermediate-1-risk myelodysplastic syndromes ( MDS ) patients who have the deletion 5q cytogenetic abnormality and no other cytogenetic abnormalities, are dependent on red blood cell transfusions, and for whom other treatment options have been found to be insufficient or inadequate.